nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—hypertension—adrenal gland cancer	0.683	1	CtDrD
Carvedilol—ABCB1—adrenal gland cancer	0.17	1	CbGaD
Carvedilol—SELE—vein—adrenal gland cancer	0.00947	0.143	CbGeAlD
Carvedilol—VCAM1—vein—adrenal gland cancer	0.00871	0.132	CbGeAlD
Carvedilol—ADRB3—brown adipose tissue—adrenal gland cancer	0.00689	0.104	CbGeAlD
Carvedilol—NPPB—adrenal cortex—adrenal gland cancer	0.00217	0.0329	CbGeAlD
Carvedilol—NPPB—cardiac atrium—adrenal gland cancer	0.0018	0.0272	CbGeAlD
Carvedilol—SELE—adrenal cortex—adrenal gland cancer	0.00147	0.0222	CbGeAlD
Carvedilol—VCAM1—adrenal cortex—adrenal gland cancer	0.00135	0.0204	CbGeAlD
Carvedilol—HIF1A—adrenal cortex—adrenal gland cancer	0.0013	0.0196	CbGeAlD
Carvedilol—GJA1—adrenal cortex—adrenal gland cancer	0.00126	0.0191	CbGeAlD
Carvedilol—SELE—pituitary gland—adrenal gland cancer	0.00119	0.0179	CbGeAlD
Carvedilol—CYP1A2—urine—adrenal gland cancer	0.00117	0.0176	CbGeAlD
Carvedilol—VCAM1—cardiac atrium—adrenal gland cancer	0.00112	0.0169	CbGeAlD
Carvedilol—CYP2C9—urine—adrenal gland cancer	0.00111	0.0167	CbGeAlD
Carvedilol—NDUFC2—adrenal cortex—adrenal gland cancer	0.0011	0.0166	CbGeAlD
Carvedilol—VCAM1—pituitary gland—adrenal gland cancer	0.00109	0.0165	CbGeAlD
Carvedilol—HIF1A—gonad—adrenal gland cancer	0.00108	0.0163	CbGeAlD
Carvedilol—HIF1A—cardiac atrium—adrenal gland cancer	0.00108	0.0162	CbGeAlD
Carvedilol—SELE—adrenal gland—adrenal gland cancer	0.00106	0.016	CbGeAlD
Carvedilol—HIF1A—pituitary gland—adrenal gland cancer	0.00105	0.0159	CbGeAlD
Carvedilol—CYP2E1—urine—adrenal gland cancer	0.00105	0.0159	CbGeAlD
Carvedilol—GJA1—gonad—adrenal gland cancer	0.00104	0.0158	CbGeAlD
Carvedilol—GJA1—cardiac atrium—adrenal gland cancer	0.00104	0.0158	CbGeAlD
Carvedilol—GJA1—pituitary gland—adrenal gland cancer	0.00102	0.0154	CbGeAlD
Carvedilol—VEGFA—adrenal cortex—adrenal gland cancer	0.000996	0.015	CbGeAlD
Carvedilol—VCAM1—adrenal gland—adrenal gland cancer	0.000975	0.0147	CbGeAlD
Carvedilol—HIF1A—adrenal gland—adrenal gland cancer	0.000938	0.0142	CbGeAlD
Carvedilol—GJA1—adrenal gland—adrenal gland cancer	0.00091	0.0138	CbGeAlD
Carvedilol—NDUFC2—gonad—adrenal gland cancer	0.000909	0.0137	CbGeAlD
Carvedilol—NDUFC2—cardiac atrium—adrenal gland cancer	0.000908	0.0137	CbGeAlD
Carvedilol—NDUFC2—pituitary gland—adrenal gland cancer	0.000887	0.0134	CbGeAlD
Carvedilol—CYP3A4—urine—adrenal gland cancer	0.000844	0.0128	CbGeAlD
Carvedilol—CYP2D6—urine—adrenal gland cancer	0.000831	0.0126	CbGeAlD
Carvedilol—VEGFA—cardiac atrium—adrenal gland cancer	0.000824	0.0124	CbGeAlD
Carvedilol—VEGFA—pituitary gland—adrenal gland cancer	0.000804	0.0122	CbGeAlD
Carvedilol—NDUFC2—adrenal gland—adrenal gland cancer	0.000792	0.012	CbGeAlD
Carvedilol—VEGFA—adrenal gland—adrenal gland cancer	0.000719	0.0109	CbGeAlD
Carvedilol—ADRB1—cardiac atrium—adrenal gland cancer	0.000391	0.00591	CbGeAlD
Carvedilol—ADRA2C—adrenal cortex—adrenal gland cancer	0.000356	0.00538	CbGeAlD
Carvedilol—KCNH2—cardiac atrium—adrenal gland cancer	0.000298	0.00451	CbGeAlD
Carvedilol—ADRA2C—cardiac atrium—adrenal gland cancer	0.000294	0.00445	CbGeAlD
Carvedilol—KCNH2—pituitary gland—adrenal gland cancer	0.000292	0.00441	CbGeAlD
Carvedilol—ADRA2C—pituitary gland—adrenal gland cancer	0.000288	0.00435	CbGeAlD
Carvedilol—ADRA1A—adrenal gland—adrenal gland cancer	0.00027	0.00408	CbGeAlD
Carvedilol—KCNH2—adrenal gland—adrenal gland cancer	0.00026	0.00394	CbGeAlD
Carvedilol—ADRA2C—adrenal gland—adrenal gland cancer	0.000257	0.00388	CbGeAlD
Carvedilol—CYP1A1—cardiac atrium—adrenal gland cancer	0.000252	0.00381	CbGeAlD
Carvedilol—ADRA2A—gonad—adrenal gland cancer	0.000235	0.00356	CbGeAlD
Carvedilol—ADRA2A—cardiac atrium—adrenal gland cancer	0.000235	0.00355	CbGeAlD
Carvedilol—ADRA2A—pituitary gland—adrenal gland cancer	0.00023	0.00347	CbGeAlD
Carvedilol—PTGS1—cardiac atrium—adrenal gland cancer	0.000221	0.00335	CbGeAlD
Carvedilol—PTGS1—pituitary gland—adrenal gland cancer	0.000216	0.00327	CbGeAlD
Carvedilol—ADRA2A—adrenal gland—adrenal gland cancer	0.000205	0.0031	CbGeAlD
Carvedilol—CYP2E1—adrenal gland—adrenal gland cancer	0.000201	0.00303	CbGeAlD
Carvedilol—PTGS1—adrenal gland—adrenal gland cancer	0.000193	0.00292	CbGeAlD
Carvedilol—ABCB1—adrenal cortex—adrenal gland cancer	0.000158	0.00239	CbGeAlD
Carvedilol—ABCB1—gonad—adrenal gland cancer	0.000131	0.00198	CbGeAlD
Carvedilol—ABCB1—pituitary gland—adrenal gland cancer	0.000128	0.00193	CbGeAlD
Carvedilol—ABCB1—adrenal gland—adrenal gland cancer	0.000114	0.00173	CbGeAlD
Carvedilol—ADRA1B—Signaling Pathways—SPRY2—adrenal gland cancer	1.44e-05	0.000178	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	1.43e-05	0.000178	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MEN1—adrenal gland cancer	1.43e-05	0.000177	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TSHR—adrenal gland cancer	1.42e-05	0.000176	CbGpPWpGaD
Carvedilol—XDH—Metabolism—POMC—adrenal gland cancer	1.42e-05	0.000176	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—adrenal gland cancer	1.42e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MEN1—adrenal gland cancer	1.41e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CDC42—adrenal gland cancer	1.41e-05	0.000175	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PRKACA—adrenal gland cancer	1.4e-05	0.000174	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—GNAS—adrenal gland cancer	1.4e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TSHR—adrenal gland cancer	1.4e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GNRH1—adrenal gland cancer	1.39e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—GNAS—adrenal gland cancer	1.38e-05	0.000171	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—MED12—adrenal gland cancer	1.36e-05	0.000168	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—GNAS—adrenal gland cancer	1.35e-05	0.000167	CbGpPWpGaD
Carvedilol—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	1.35e-05	0.000167	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MEN1—adrenal gland cancer	1.34e-05	0.000165	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—adrenal gland cancer	1.32e-05	0.000164	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MEN1—adrenal gland cancer	1.31e-05	0.000163	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	1.31e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	1.3e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CDC42—adrenal gland cancer	1.28e-05	0.000159	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SPRY2—adrenal gland cancer	1.27e-05	0.000158	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TERT—adrenal gland cancer	1.26e-05	0.000156	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TERT—adrenal gland cancer	1.26e-05	0.000156	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—RRM1—adrenal gland cancer	1.26e-05	0.000156	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SDHD—adrenal gland cancer	1.26e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	1.25e-05	0.000155	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—MED12—adrenal gland cancer	1.25e-05	0.000154	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TSHR—adrenal gland cancer	1.24e-05	0.000154	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—POMC—adrenal gland cancer	1.23e-05	0.000152	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	1.23e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—GNAS—adrenal gland cancer	1.22e-05	0.000152	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PRKACA—adrenal gland cancer	1.22e-05	0.000151	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PRKACA—adrenal gland cancer	1.22e-05	0.000151	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PRKACA—adrenal gland cancer	1.21e-05	0.00015	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SDHB—adrenal gland cancer	1.2e-05	0.000149	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	1.19e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	1.19e-05	0.000147	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—RRM1—adrenal gland cancer	1.19e-05	0.000147	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SDHD—adrenal gland cancer	1.19e-05	0.000147	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	1.19e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	1.18e-05	0.000147	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SDHD—adrenal gland cancer	1.18e-05	0.000146	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—RRM1—adrenal gland cancer	1.18e-05	0.000146	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—MED12—adrenal gland cancer	1.18e-05	0.000146	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MEN1—adrenal gland cancer	1.17e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	1.15e-05	0.000143	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	1.14e-05	0.000141	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	1.14e-05	0.000141	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTGS2—adrenal gland cancer	1.13e-05	0.00014	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—POMC—adrenal gland cancer	1.12e-05	0.000139	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—POMC—adrenal gland cancer	1.12e-05	0.000138	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—adrenal gland cancer	1.11e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—POMC—adrenal gland cancer	1.11e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PRKACA—adrenal gland cancer	1.1e-05	0.000136	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—BAD—adrenal gland cancer	1.1e-05	0.000136	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—BAD—adrenal gland cancer	1.1e-05	0.000136	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—POMC—adrenal gland cancer	1.1e-05	0.000136	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PRKACA—adrenal gland cancer	1.09e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	1.09e-05	0.000134	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PRKACA—adrenal gland cancer	1.08e-05	0.000134	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.05e-05	0.00013	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—POMC—adrenal gland cancer	1.04e-05	0.000129	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CDC42—adrenal gland cancer	1.03e-05	0.000127	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—POMC—adrenal gland cancer	1.02e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PRKACA—adrenal gland cancer	1.02e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—POMC—adrenal gland cancer	1.02e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—POMC—adrenal gland cancer	1.01e-05	0.000125	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—POMC—adrenal gland cancer	1.01e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—POMC—adrenal gland cancer	1.01e-05	0.000125	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—RRM1—adrenal gland cancer	1.01e-05	0.000125	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SDHD—adrenal gland cancer	1.01e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PRKACA—adrenal gland cancer	1e-05	0.000124	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—BRAF—adrenal gland cancer	1e-05	0.000124	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—BRAF—adrenal gland cancer	9.98e-06	0.000124	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—POMC—adrenal gland cancer	9.96e-06	0.000123	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	9.91e-06	0.000123	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IGF2—adrenal gland cancer	9.89e-06	0.000122	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GNAS—adrenal gland cancer	9.89e-06	0.000122	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GNAS—adrenal gland cancer	9.87e-06	0.000122	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—GNAS—adrenal gland cancer	9.8e-06	0.000121	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ABCB1—adrenal gland cancer	9.7e-06	0.00012	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—adrenal gland cancer	9.7e-06	0.00012	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ABCB1—adrenal gland cancer	9.68e-06	0.00012	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IGF1R—adrenal gland cancer	9.56e-06	0.000118	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	9.54e-06	0.000118	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—POMC—adrenal gland cancer	9.42e-06	0.000117	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MED12—adrenal gland cancer	9.39e-06	0.000116	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDC42—adrenal gland cancer	9.35e-06	0.000116	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—POMC—adrenal gland cancer	9.27e-06	0.000115	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDC42—adrenal gland cancer	9.26e-06	0.000115	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDC42—adrenal gland cancer	9.14e-06	0.000113	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PRKACA—adrenal gland cancer	9.1e-06	0.000113	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—POMC—adrenal gland cancer	9.07e-06	0.000112	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IGF2—adrenal gland cancer	9.01e-06	0.000112	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—GNAS—adrenal gland cancer	8.93e-06	0.000111	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IGF2—adrenal gland cancer	8.93e-06	0.000111	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PRKACA—adrenal gland cancer	8.92e-06	0.00011	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MED12—adrenal gland cancer	8.85e-06	0.00011	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—GNAS—adrenal gland cancer	8.85e-06	0.00011	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IGF2—adrenal gland cancer	8.81e-06	0.000109	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MED12—adrenal gland cancer	8.77e-06	0.000109	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—GNAS—adrenal gland cancer	8.74e-06	0.000108	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IGF1R—adrenal gland cancer	8.71e-06	0.000108	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDC42—adrenal gland cancer	8.65e-06	0.000107	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IGF1R—adrenal gland cancer	8.63e-06	0.000107	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PRKACA—adrenal gland cancer	8.58e-06	0.000106	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IGF1R—adrenal gland cancer	8.52e-06	0.000106	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDC42—adrenal gland cancer	8.51e-06	0.000105	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	8.43e-06	0.000104	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	8.38e-06	0.000104	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—adrenal gland cancer	8.34e-06	0.000103	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF2—adrenal gland cancer	8.34e-06	0.000103	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	8.28e-06	0.000103	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—GNAS—adrenal gland cancer	8.27e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—POMC—adrenal gland cancer	8.24e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TERT—adrenal gland cancer	8.23e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF2—adrenal gland cancer	8.21e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—GNAS—adrenal gland cancer	8.14e-06	0.000101	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IGF1R—adrenal gland cancer	8.06e-06	9.99e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GNAS—adrenal gland cancer	8.03e-06	9.95e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IGF1R—adrenal gland cancer	7.93e-06	9.83e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	7.88e-06	9.76e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	7.84e-06	9.71e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—adrenal gland cancer	7.79e-06	9.65e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SDHD—adrenal gland cancer	7.76e-06	9.61e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—RRM1—adrenal gland cancer	7.76e-06	9.61e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	7.65e-06	9.48e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDC42—adrenal gland cancer	7.56e-06	9.37e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TERT—adrenal gland cancer	7.5e-06	9.29e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MED12—adrenal gland cancer	7.5e-06	9.29e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TERT—adrenal gland cancer	7.43e-06	9.2e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GNAS—adrenal gland cancer	7.37e-06	9.13e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TERT—adrenal gland cancer	7.33e-06	9.09e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF2—adrenal gland cancer	7.29e-06	9.03e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ABCB1—adrenal gland cancer	7.24e-06	8.96e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CTNNB1—adrenal gland cancer	7.23e-06	8.96e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GNAS—adrenal gland cancer	7.23e-06	8.95e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CTNNB1—adrenal gland cancer	7.22e-06	8.94e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—BAD—adrenal gland cancer	7.16e-06	8.87e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1R—adrenal gland cancer	7.05e-06	8.73e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	7.03e-06	8.7e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GNAS—adrenal gland cancer	6.95e-06	8.61e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TERT—adrenal gland cancer	6.94e-06	8.6e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PRKACA—adrenal gland cancer	6.85e-06	8.49e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TERT—adrenal gland cancer	6.83e-06	8.46e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ABCB1—adrenal gland cancer	6.82e-06	8.45e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	6.77e-06	8.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	6.71e-06	8.32e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.7e-06	8.3e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—POMC—adrenal gland cancer	6.66e-06	8.24e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—POMC—adrenal gland cancer	6.64e-06	8.23e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—POMC—adrenal gland cancer	6.6e-06	8.17e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	6.55e-06	8.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—BAD—adrenal gland cancer	6.52e-06	8.08e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—BRAF—adrenal gland cancer	6.52e-06	8.07e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—BAD—adrenal gland cancer	6.46e-06	8.01e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	6.46e-06	8e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	6.4e-06	7.93e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—BAD—adrenal gland cancer	6.38e-06	7.9e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—adrenal gland cancer	6.33e-06	7.84e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—adrenal gland cancer	6.32e-06	7.82e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	6.26e-06	7.75e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TERT—adrenal gland cancer	6.07e-06	7.51e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—BAD—adrenal gland cancer	6.04e-06	7.48e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—POMC—adrenal gland cancer	6.01e-06	7.45e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—POMC—adrenal gland cancer	5.96e-06	7.38e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BAD—adrenal gland cancer	5.94e-06	7.36e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—BRAF—adrenal gland cancer	5.94e-06	7.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—BRAF—adrenal gland cancer	5.88e-06	7.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—POMC—adrenal gland cancer	5.88e-06	7.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—BRAF—adrenal gland cancer	5.81e-06	7.19e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MED12—adrenal gland cancer	5.79e-06	7.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—adrenal gland cancer	5.76e-06	7.13e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—adrenal gland cancer	5.73e-06	7.1e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—adrenal gland cancer	5.72e-06	7.08e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—adrenal gland cancer	5.7e-06	7.06e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	5.64e-06	6.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—adrenal gland cancer	5.63e-06	6.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—POMC—adrenal gland cancer	5.57e-06	6.89e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GNAS—adrenal gland cancer	5.55e-06	6.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—BRAF—adrenal gland cancer	5.5e-06	6.81e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—POMC—adrenal gland cancer	5.48e-06	6.78e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	5.47e-06	6.77e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BRAF—adrenal gland cancer	5.41e-06	6.7e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—POMC—adrenal gland cancer	5.41e-06	6.7e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.35e-06	6.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—adrenal gland cancer	5.33e-06	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—adrenal gland cancer	5.31e-06	6.58e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—adrenal gland cancer	5.3e-06	6.56e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BAD—adrenal gland cancer	5.28e-06	6.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—adrenal gland cancer	5.24e-06	6.49e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GNAS—adrenal gland cancer	5.23e-06	6.48e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GNAS—adrenal gland cancer	5.19e-06	6.42e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	5.13e-06	6.36e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	5.09e-06	6.3e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—POMC—adrenal gland cancer	4.96e-06	6.15e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	4.9e-06	6.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—POMC—adrenal gland cancer	4.87e-06	6.03e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—adrenal gland cancer	4.81e-06	5.96e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—adrenal gland cancer	4.8e-06	5.95e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—adrenal gland cancer	4.8e-06	5.94e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—adrenal gland cancer	4.71e-06	5.83e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—POMC—adrenal gland cancer	4.68e-06	5.8e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—adrenal gland cancer	4.66e-06	5.77e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	4.52e-06	5.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	4.46e-06	5.53e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GNAS—adrenal gland cancer	4.43e-06	5.49e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	4.35e-06	5.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	4.33e-06	5.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	4.31e-06	5.34e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—adrenal gland cancer	4.29e-06	5.32e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—adrenal gland cancer	4.25e-06	5.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	4.22e-06	5.23e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—adrenal gland cancer	4.2e-06	5.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—adrenal gland cancer	3.97e-06	4.92e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—adrenal gland cancer	3.96e-06	4.9e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—adrenal gland cancer	3.91e-06	4.84e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—POMC—adrenal gland cancer	3.74e-06	4.63e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—adrenal gland cancer	3.73e-06	4.62e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—adrenal gland cancer	3.73e-06	4.62e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—POMC—adrenal gland cancer	3.52e-06	4.36e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—POMC—adrenal gland cancer	3.49e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—adrenal gland cancer	3.47e-06	4.3e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GNAS—adrenal gland cancer	3.42e-06	4.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—adrenal gland cancer	3.4e-06	4.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—adrenal gland cancer	3.37e-06	4.17e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	3.36e-06	4.16e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—adrenal gland cancer	3.33e-06	4.12e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	3.23e-06	4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—adrenal gland cancer	3.15e-06	3.9e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—adrenal gland cancer	3.13e-06	3.88e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—adrenal gland cancer	3.1e-06	3.84e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—POMC—adrenal gland cancer	2.98e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—adrenal gland cancer	2.98e-06	3.69e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—adrenal gland cancer	2.85e-06	3.54e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—adrenal gland cancer	2.83e-06	3.5e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	2.81e-06	3.48e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—adrenal gland cancer	2.79e-06	3.46e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	2.79e-06	3.45e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—adrenal gland cancer	2.75e-06	3.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—adrenal gland cancer	2.64e-06	3.27e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—adrenal gland cancer	2.6e-06	3.22e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	2.56e-06	3.17e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	2.38e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—adrenal gland cancer	2.31e-06	2.86e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—POMC—adrenal gland cancer	2.3e-06	2.85e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	2.15e-06	2.66e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	1.84e-06	2.28e-05	CbGpPWpGaD
